Pharmaceutical regulation

The life sciences sector encompasses companies in the fields of pharmaceuticals, biotechnology and medical technology that focus on the research, development and commercialisation of a wide range of products that have a medical application. Such products include pharmaceuticals (ie everything from over-the-counter painkillers to advanced therapies for treating diseases such as cancer or HIV), medical devices (eg plasters, syringes, heart stents, pacemakers, etc) and diagnostics. This subtopic provides an overview of pharmaceutical regulation in the EU.

In the EU, a large amount of the regulation originates from directives or regulations and is supplemented by guidance issued by the European Commission and by the European Medicines Agency (EMA), the decentralised agency of the EU responsible for the scientific evaluation, supervision and safety monitoring of medicines.

Regulation of medicinal products

Article 1(2) of Directive 2001/83/EC, the Pharmaceutical Code defines a medicinal product as a substance that is either:

  1. presented as preventing or treating disease, or

  2. used to correct or modify a physiological function by pharmacological, immunological or metabolic action, or to make a medical diagnosis

Practice Note: Introduction to the regulation of medicinal products—EU provides an

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

Powered by Lexis+®
Latest EU Law News

EU Law weekly highlights—24 July 2025

This week's edition of EU Law weekly highlights includes analyses on the decision of the EU court for privacy activist Lisa Ballmann to access files in the Meta case, the EU trade mark dispute on Iceland foods which lost over link to nation's name, the Commission’s guidelines on the EU AI Act’s rules for general-purpose AI models, the final version of the General-Purpose AI Code of Practice, the country's first national collective database to be licensed for training AI formed by a group of Dutch media outlets, the Commission’s guidelines for the protection of minors online and a Market Insights Trend Report’s analysis on the sustainability disclosures and climate transition plans. In addition this week, the Commission proposed a new Multiannual Financial Framework, published the July 2025 infringement package, initiated procedures to adopt new adequacy decisions for EU-UK personal data transfers, initiated a call for evidence seeking input on a future omnibus package to simplify environmental legislation, published an Explanatory Notice and Template to guide providers of General Purpose AI models and launched a consultation for its proposed Digital Fairness Act. Further, the Council of the EU adopted a regulation modifying the Entry/Exit System implementation framework, adopted a regulation postponing the application of due diligence obligations under the EU Batteries Regulation and adopted amendments to extend the gas storage regulation by two years beyond its current 2025 expiry date.

View EU Law by content type :

Popular documents